Celator Announces Trial Results For CPX-1 In Colorectal Cancer Treatment

Armen Hareyan's picture

Celator Pharmaceuticals reported positive results from its CPX-1 Phase 2 clinical trial in patients with advanced colorectal cancer. CPX-1 is a liposomal formulation of irinotecan and floxuridine, based on the company's proprietary CombiPlex technology. The results were presented in a poster presentation at the American Society of Clinical Oncology meeting in Chicago.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.